DCIS (ductal carcinoma in situ) is a non-invasive cancer that originates in the basement membrane of the breast ductal system. DCIS has a wide range of natural histories, with estimated rates of progression to invasive ductal carcinoma ranging from 20% to 53% ten years or more after the first diagnosis. In the last two decades, DCIS surgical and adjuvant care has come a long way. Regardless, surgeons, medical oncologists, and radiation oncologists, as well as their patients, continue to base treatment decisions on traditional clinical and pathologic risk factors. DCIS and invasive carcinoma coexisting in the same lesion suggests that DCIS is a precursor to invasive cancer. Regardless of management strategy, long-term survival is excellent. The problem with DCIS is that it is difficult to prevent either under- or over-treatment. The goal of this chapter is to go through DCIS's incidence and treatment options. We'll look at some of the current debates around DCIS treatment, such as the role of radiation in breast conserving surgery, sentinel node biopsy in DCIS, hormone therapy, risk classification, and the option of active surveillance for low-risk DCIS.
Author(S) Details
Fernando Cordera
Sociedad Quirúrgica
S.C. at the American British Cowdray Medical Center, Av. Carlos Graef Fernández
# 154 – 515, Colonia Tlaxala, Delegación Cuajimalpa, Mexico City 05300, Mexico.
Rodrigo Arrangoiz
Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center,
Av. Carlos Graef Fernández # 154 – 515, Colonia Tlaxala, Delegación Cuajimalpa,
Mexico City 05300, Mexico.
View Book:- https://stm.bookpi.org/NHMMR-V5/article/view/6487
No comments:
Post a Comment